NDLI: Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review

Please wait, while we are loading the content...

Prohypertensive Effect of Gestational Personal Exposure to Fine Particulate Matter. Prospective Cohort Study in Non-smoking and Non-obese Pregnant Women

Cardiac and Vascular Atrogin-1 mRNA Expression is Not Associated with Dexamethasone Efficacy in the Monocrotaline Model of Pulmonary Hypertension

Combined Effects of Quercetin and Atenolol in Reducing Isoproterenol-Induced Cardiotoxicity in Rats: Possible Mediation Through Scavenging Free Radicals

Cardiovascular Responses to Bothrops alternatus (Urutu) Snake Venom in Anesthetized Dogs

Acute Massive Pulmonary Thromboembolism Due to Acute Intoxication by Duloxetine: A Case Report

Case Report: An Unusual Heart Rhythm Associated with Organophosphate Poisoning

A Patient with Leiden V Mutation, Multiple Sclerosis, Psoriasis, and Sicca Syndrome: Could Celecoxib and Fingolimod Adversely Affect the Heart?

With Which Mechanism the Overuse of Energy Drinks May Induce Acute Myocardial Ischemia?

Cardiovascular Toxicology : Volume 12, Issue 2, June 2012

Cardiovascular Toxicology : Volume 12, Issue 1, March 2012

Cardiovascular Toxicology : Volume 11

Cardiovascular Toxicology : Volume 10

Cardiovascular Toxicology : Volume 9

Cardiovascular Toxicology : Volume 8

Cardiovascular Toxicology : Volume 7

Cardiovascular Toxicology : Volume 6

Cardiovascular Toxicology : Volume 5

Cardiovascular Toxicology : Volume 4

Cardiovascular Toxicology : Volume 3

Cardiovascular Toxicology : Volume 2

Cardiovascular Toxicology : Volume 1

Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review

Content Provider	Springer Nature Link
Author	Svoboda, Marek Poprach, Alexandr Dobes, Svatopluk Kiss, Igor Vyzula, Rostislav
Copyright Year	2012
Abstract	Cardiotoxicity associated with conventional cytostatics is a known phenomenon and is related to their general cytotoxic effects. This damage to the myocardium is usually irreversible. Despite the attempts to optimize safety profile of targeted anticancer drugs during their development, evidence shows that these new treatment modalities also have cardiotoxic potential or may adversely affect vascular system. Over the last years, a significant number of these agents have been introduced in medical practice. Arterial hypertension, arrhythmias, left ventricular dysfunction and a heart failure are the most frequent cardiovascular adverse effects of targeted anticancer agents, but this toxicity seems to be reversible. To enable early interventions and to minimize these cardiovascular adverse effects, health care professionals have to be well-informed and familiar with the safety profiles of the drugs they administered, the patient’s cardiovascular condition and co-morbidities, and they must regularly monitor their patients for potential adverse effects. The aim of this paper is to provide an overview of cardiotoxic effects caused by targeted anticancer drugs used in the treatment of solid tumours. We discuss pathophysiological mechanisms, diagnostics and treatment, risk factors and options for prevention.
Starting Page	191
Ending Page	207
Page Count	17
File Format	PDF
ISSN	15307905
Journal	Cardiovascular Toxicology
Volume Number	12
Issue Number	3
e-ISSN	15590259
Language	English
Publisher	Humana Press Inc
Publisher Date	2012-04-22
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Cardiotoxicity Targeted therapy Monoclonal antibodies Protein kinase inhibitors Left ventricular dysfunction Hypertension QT interval Cancer Pharmacology/Toxicology Cardiology
Content Type	Text
Resource Type	Article
Subject	Molecular Biology Toxicology Cardiology and Cardiovascular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Cancer therapy related cardiac dysfunction as a result of Panitumumab

Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction

Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Late cardiotoxicity related to HER2-targeted cancer therapy

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction

Concepts in cardiac oncology

Usefulness of Electrocardiographic QT Interval to Predict Left Ventricular Diastolic Dysfunction

Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review

Similar Documents

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Cancer therapy related cardiac dysfunction as a result of Panitumumab

Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction

Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Late cardiotoxicity related to HER2-targeted cancer therapy

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction

Concepts in cardiac oncology

Usefulness of Electrocardiographic QT Interval to Predict Left Ventricular Diastolic Dysfunction

Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review